Vir Biotechnology Inc. is a clinical-stage biopharmaceutical company dedicated to enhancing the immune system to improve treatment and prevention strategies for serious infectious diseases, including chronic hepatitis B and hepatitis delta, as well as certain cancers. Through its dual technology platforms, Vir develops innovative therapies that leverage natural immune processes. The company's robust pipeline includes both clinical-stage programs targeting significant viral infections and preclinical candidates aimed at additional infectious diseases. Vir is committed to fostering a workplace rooted in equality, inclusion, and respect, believing that the success of its employees is integral to accomplishing its mission. This collaborative environment encourages individuals to contribute their best, ultimately driving impactful results in the realm of immunology and drug development.